CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

HSBC Upgrades Gilead Sciences to Buy From Hold, Adjusts Price Target to $155 From $133

Positive
AI Analysis

Summary

HSBC upgraded Gilead Sciences from Hold to Buy and raised its price target from $133 to $155 per share.

Importance:2/10
Sentiment:
0.65
analyst upgradeprice target increaseequity research
Related Companies

Read the original article

Published by yahoo_finance on July 6, 2026 11:46 AM

Read Original